Nuvalent | 8-K: Current report
Nuvalent | 8-K: Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
Nuvalent | DEFA14A: Others
Nuvalent | DEF 14A: Definitive information statements
Nuvalent | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Nuvalent | 8-K: Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
Nuvalent | 8-K: Current report
Nuvalent | 8-K: Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
Nuvalent | 8-K: Current report
Nuvalent | 8-K: Current report
Nuvalent | 8-K: Current report
Nuvalent | 8-K: Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
Nuvalent | 8-K: Current report
Nuvalent | 8-K: Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
Nuvalent | DEFA14A: Others
Nuvalent | DEF 14A: Definitive proxy statements
Nuvalent | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition
Nuvalent | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Nuvalent | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Nuvalent | 8-K: Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
No Data